Michael P. Schittkowski

Prof. Dr. Michael P. Schittkowski

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Ophthalmology
Verified
Journal Article
Open access
MYMichael T. Yen
Michael T. Yen
KCKimberly Cockerham
Kimberly Cockerham
PSPeerooz Saeed
Peerooz Saeed
SLSteven Leibowitz
Steven Leibowitz
RMRaghu C. Mudumbai
Raghu C. Mudumbai
MTMadhura Tamhankar
Madhura Tamhankar
Thyroid eye disease (TED) is a debilitating autoimmune disease with significant unmet needs. This study's objective was to assess the efficacy and safety of veligrotug, a full antagonist monoclonal antibody to the insulin-like growth factor-1 receptor, in patients with active TED. Veligrotug was assessed in THRIVE, a global, multicenter, randomized, double-masked, placebo-controlled phase 3 trial. Adult patients with moderate-to-severe active TED (onset ≤ 15 months, proptosis ≥ 3 mm above normal, and clinical activity score [CAS] ≥ 3) received either veligrotug or placebo. Patients were randomized 2:1 to receive 10 mg/kg veligrotug or placebo administered every 3 weeks for a total of 5 IV infusions. The primary end point at week 15 was the proptosis responder rate (PRR; ≥ 2-mm reduction by Hertel exophthalmometry) or overall responder rate (ORR; PRR and ≥ 2-point reduction in CAS), depending on geographic region. Efficacy and safety were assessed through week 52. A total of 113 patients received veligrotug (n = 75) or placebo (n = 38). Baseline characteristics were balanced between the 2 arms. Improvements were observed at week 3, with a significantly greater response at week 15 for veligrotug versus placebo (P < 0.001) across all primary and secondary end points including: PRR by Hertel, 70% versus 5%; PRR by magnetic resonance imaging (MRI) or computed tomography (CT), 71% versus 9%; ORR, 67% versus 5%; mean proptosis reduction, 2.90 mm versus 0.48 mm (Hertel) and 2.96 mm versus 0.58 mm (MRI/CT); diplopia improvement, 59% versus 20%; and diplopia resolution, 49% versus 12%. At week 52, 70% of initial responders maintained proptosis response. Veligrotug was generally well tolerated, with a 4% treatment discontinuation rate. Most adverse events were mild and resolved, with no serious treatment-related adverse events and no changes in the safety profile through week 52. A 5-infusion course of veligrotug administered over 12 weeks was generally well tolerated and led to rapid and significant improvements in diplopia, proptosis, and disease activity, with a durable response through week 52. Veligrotug may become a promising new treatment option for active TED. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

16 February 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
MSMichael P. Schittkowski
Michael P. Schittkowski
JPJohanna Pohlner
Johanna Pohlner
KMKarl Mercieca
Karl Mercieca
CGCarsten Grohmann
Carsten Grohmann
LKLena Kröger
Lena Kröger
AAAndrea Antal
Andrea Antal
Introduction Glaucoma is one of the most common causes of blindness and affects more than 70 million people worldwide. The disease is characterised by the loss of retinal ganglion cells associated with a progressive optic neuropathy, resulting in an impairment of visual functions, for example, visual field loss. Nowadays, the only modifiable risk factor is the increase in intraocular pressure, and its treatment is to lower this pressure by medication, laser treatment or surgery to avoid disease progression. New methods for preventing and reversing vision loss are thus urgently needed. Several small and two multicentre studies have presented evidence that repetitive transorbital alternating current stimulation (rtACS) can lead to long-lasting visual field improvement. This could open a new and inexpensive therapeutic option for optic atrophy. However, the level of evidence for this method is still fairly rather poor, and further trials are needed. Therefore, this clinical trial aims to prove the effectiveness of rtACS compared with sham stimulation in patients with primary open-angle glaucoma (POAG). Methods and analysis VIRON (Vision Restoration in Optic Neuropathy) is a national, multicentre, prospective, randomised, placebo-controlled, double-blind trial with three arms. The primary objective is to assess the effectiveness of rtACS in patients with POAG compared with sham stimulation. The primary outcome is the change in mean defect (MD) in the visual field immediately after 10 sessions of rtACS (days 9, 16 and 23) compared with the values of initial perimetry (days −21 to –14 and 0) after applying electrical stimulation with a classical montage, compared with sham and electrical stimulation using individualised montage. Secondary outcome measures comprise a long-term effect with changes in MD at 24 weeks after stimulation, and data from the National Eye Institute Visual Function-25 and quality of life (Short Form 36) questionnaires. The target population are patients with glaucomatous optic atrophy and significant glaucomatous visual field defects (MD of 5–22 dB) due to POAG. After randomisation, patients received either classical rtACS (group 1), individual rtACS (group 2) or sham stimulation (group 3) in daily 25 min stimulation sessions in two series of five consecutive days separated by a weekend interval. In group 1, active stimulation will be via the routinely applied montage using two electrodes affixed on the right and left side of the head, next to the eyes, with straightforward fixation. In group 2, the current flow will be individually modelled (MRI-based) to target areas of partial visual field defects by optimising electrode positions in conjunction with an optimised visual fixation direction. Group 3 with sham stimulation will serve as control. The calculated sample size required to achieve a statistical power of 80% for a relevant effect size and allow for dropouts was 300 (100 per group). The trial has already begun with the first patient in July 2023. The planned recruitment period is 24 months with an estimated end of the study in November 2025 (last patient out). An adjusted extension of the study period is planned. Ethics and dissemination VIRON was approved by the Central Ethics Committee of the University Medical Center Göttingen (19 October 2022) and those of the individual participating centres (Bonn: 446/23-EP, Hamburg: 2023-200889-BO-bet, Cologne: 23-1487 and Mainz: 2023-17399-§23b). The study protocol complies with the Declaration of Helsinki, the national medicine device regulation (MDR) laws and the international standards of good clinical practice (GCP). The study protocol (V.5, 24 November 2023) was designed following the Standard Protocol Items: Recommendations for Interventional Trials guidelines and is registered on https://drks.de/search/de/trial/DRKS00029129. As study initiatior the University Medical Center Göttingen (UMG) is responsible for data ownership and data management of the VIRON study. The study data will be published within 6 months of the study being completed. After the publication of the primary results, all data are anonymised and published in an open-access journal to ensure access to the data for third parties. Trial registration number https://drks.de/search/de/trial/DRKS00029129.

1 January 2022 in Klinische Monatsblätter für Augenheilkunde
Verified
Journal Article
Closed access
PDF file
MSMichael P. Schittkowski
Michael P. Schittkowski
SMStefanie Martius
Stefanie Martius
MEMohamed Elabbasy
Mohamed Elabbasy
SKSteffi Knappe
Steffi Knappe
RGRudolf F. Guthoff
Rudolf F. Guthoff
Zusammenfassung: Einleitung Ein kongenitaler Mikrophthalmus kann entweder isoliert auftreten (einfacher Mikrophthalmus) oder mit weiteren okulären Fehlbildungen, wie einer Sklerokornea oder einer Katarakt, assoziiert sein (komplexer Mikrophthalmus). Aufgrund des seltenen Auftretens fehlen einheitliche Behandlungsempfehlungen. Material und Methoden Retrospektive Fallserie von 103 Patienten bzw. insgesamt 114 Augen mit kongenitalem Mikrophthalmus mit Erfassung von Alter, Geschlecht, Visus, Pupillenreaktion, axialer Bulbuslänge, horizontaler Weite der Lidspalte, Art der durchgeführten Therapie, Komplikationen. Ergebnisse Alle Patienten waren ausnahmslos primär prothesenfähig. Die Größe der Lidspalte hing vom zugrunde liegenden Befund ab: „beidseits Mikrophthalmus“ < „Mikrophthalmus und gesundes Partnerauge“ < „Mikrophthalmus und Anophthalmus der anderen Seite“. Um bei einem Säugling in den ersten Lebenswochen oder -monaten die visuelle (Rest-)Funktion als wichtigsten Faktor für die Entscheidung über die Therapie zu beurteilen, ist die Pupillenreaktion, speziell bei einseitiger Erkrankung die indirekte Lichtreaktion des gesunden Auges, von größter Bedeutung. In etwa der Hälfte der Fälle war eine konservative Prothesenbehandlung ausreichend. Nach der erfolgreichen Erstanpassung einer Vorlegeprothese fand eine regelmäßige Prothesenvergrößerung nach Maßgabe des Okularisten statt. Wenn die Bulbuslängendifferenz so groß war, dass auch mit einer doppelwandigen Prothese keine Symmetrie zu erzielen war, wurde eine Volumenauffüllung durch retrobulbär implantierte selbstquellende Pelletexpander (osmed GmbH, Ilmenau) angeboten. Bei knapp einem Drittel der Patienten erfolgte keine operative Therapie oder prothetische Versorgung. Die Ursache dafür war meist das Vorliegen einer minimalen Sehfunktion des Mikrophthalmus (Wahrnehmung von Lichtschein bis Angabe von Handbewegungen). Schlussfolgerung Bei vorhandener Sehfähigkeit des Mikrophthalmus sollten operative Maßnahmen nicht oder nur mit äußerster Zurückhaltung indiziert werden, da der Erhalt des vorhandenen Visus als vorrangig vor dem kosmetischen Befund angesehen werden muss. Bei Asymmetrie oder unterentwickelter Lidspalte kann der Therapiebeginn frühzeitig im 1. Lebensjahr erfolgen, ohne dass daraus resultierende Komplikationen zu befürchten sind.

1 April 1999 in Klinische Monatsblätter für Augenheilkunde
Verified
Journal Article
Closed access
MSMichael P. Schittkowski
Michael P. Schittkowski
VHVolker Hingst
Volker Hingst
GSGerhard Stropahl
Gerhard Stropahl
RGRudolf Guthoff
Rudolf Guthoff
In case a sonographically high reflective intraocular tumor is detected, some different processes with calcium embedding could be considered. A 56 year-old female patient was seen in our department for the first time because of secondary glaucoma of the amaurotic right eye. The left eye has had no morphological changes and visual acuity was 5/5. More than 20 years ago the patient had noticed decreased visual acuity of the right eye for the first time. 10 years ago in a first report from another eye hospital, a large white tumor in the area of the optic disc had been described. Sonographic size was 12 x 8 mm, 5.3 mm prominence. Visual acuity was perception of light with incorrect projection. A CT scan showed an inhomgeneous structure of calcification in the area of the right optic disc which continued along the optic nerve to intracranial structures. Enucleation was performed. Histopathological examination showed meningothelial meningeoma (grade I WHO) with its origin in the dural sheath of the optic nerve and intraocular growth. A postoperative MRI confirmed the intracranial spreading of the meningeoma along the dural sheath of the optical nerve. A meningeoma of the olfactorius region was found as a second independent tumor. The intraocular spread of an optical nerve sheath meningeoma is a rare case.

15 October 2020 in Klinische Monatsblätter für Augenheilkunde
Verified
Journal Article
Closed access
PDF file
NKNadja Karstädt
Nadja Karstädt
TCThomas A. Crozier
Thomas A. Crozier
MHMaren Horn
Maren Horn
SNSabine Naxer
Sabine Naxer
MSMichael P. Schittkowski
Michael P. Schittkowski
Introduction The course of the recovery phase after general anaesthesia, during which consciousness and pain gradually return, is essentially determined by the choice of anaesthetic drug, and its total dose or duration of application. This phase is often complicated by more or less severe agitation, especially in children. In the present study we investigated whether the application of a topical anaesthetic to the conjunctiva at the end of a strabismus operation had a positive effect on the recovery behaviour of the child. Patients/Methods This prospective, randomised, blinded study was conducted with 50 healthy, ASA class I or II children, aged 3 to 8 years undergoing their first strabismus operation. Following the surgeonʼs randomisation two drops of a 0,5% tetracaine-HCl ophthalmic solution were applied to the operated conjunctiva three times at 30-s intervals immediately following wound closure. The postoperative evaluation encompassed heart rate, as well as COMFORT and CHEOPS scores. The first assessment was directly postoperatively with repetitions at 15, 30, 45, 60, 75, 90 and 120 min, as well as on the day after surgery. Results The CHEOPS scores did not differ significantly between children with or without topical anaesthesia at any time during the observation period. The COMFORT scores revealed a slight, but non-significant analgesic effect at 15 and 30 min. The 60 min score showed the opposite effect, possibly indicating a slight disadvantage of the topical anaesthesia. There were no significant differences with regard to time to first request for additional systemic analgesia, to the total dose of systemic pain medication, or to when the patient was eligible for discharge to the ward. Conclusion The application of topical tetracaine-HCl immediately after wound closure had no positive effects on the course of the postoperative recovery period after strabismus surgery in children. There was no evidence of an effect on pain or emergence agitation. Received: 13 August 2020 Accepted: 09 September 2020 Article published online: 15 October 2020 © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

20 January 2023 in Die Ophthalmologie
Verified
Journal Article
Closed access
PDF file
MSMichael P. Schittkowski
Michael P. Schittkowski
NWNikolai Weiss
Nikolai Weiss